Proven Excellence in Global Contract and Toll Manufacturing Services, Pyridam Farma (PYFA) Named Best Pharmaceutical CDMO & Global Expansion Leader 2026

5 min read

KEY POINTS:

JAKARTA, October 30, 2026 – PT Pyridam Farma Tbk (IDX: PYFA) officially received the prestigious award for Best Pharmaceutical CDMO & Global Expansion Leader in the Indonesia Best Pharmaceuticals category within the Healthcare sector in Jakarta. This award was presented in recognition of PYFA’s strategic excellence in integrating Good Corporate Governance (GCG) principles, sustainability, and digital transformation, while demonstrating the resilience of its cross-border Contract Development and Manufacturing Organization (CDMO), pharmaceutical contract manufacturing, and toll manufacturing (toll-in) business model, which serves as the primary driver of the Company’s performance growth.

This achievement aligns with the rapid global healthcare industry shift toward supply chain efficiency through contract manufacturing partnerships. According to the latest global market research report from Cervicorn Consulting (2026), the global pharmaceutical CDMO market value exceeded USD 263.04 billion to USD 275 billion in 2026 and is projected to reach USD 520.27 billion by 2035, with a solid Compound Annual Growth Rate (CAGR) ranging from 7.06% to 10% annually, with the Asia-Pacific region serving as the world’s fastest-growing hub. This high demand trend for production outsourcing through contract manufacturing and toll-in (toll manufacturing) schemes from global pharmaceutical principals opens massive expansion opportunities for PYFA, which has established international-standard manufacturing infrastructure in Indonesia and Australia.

PYFA’s selection as the winner was based on the company securing the highest score from the panel of judges across four main evaluation pillars: largest CDMO performance, most progressive CDMO innovation, best operational efficiency, and commitment to sustainability and global expansion. These operational achievements align with PYFA’s financial performance, which has drawn key attention from capital market players. In the full-year FY 2025 financial statements, PYFA’s revenue grew rapidly by 43.7% to reach IDR 2.7 trillion from IDR 1.9 trillion in FY 2024, with CDMO services consistently driving revenue increases across the last two reporting periods.

Head of CDMO PYFA for Indonesian operations, Savira Tjan, stated that this award serves as clear proof of PYFA’s superior partnerships with various multinational companies and top-tier corporations in Indonesia. As a representative of the Company, she highlighted that PYFA’s competitive advantage lies in the company’s ability to deliver innovative product solutions along with extensive service support for all clients. These capabilities are considered highly relevant in capturing opportunities amid the dynamic growth of the pharmaceutical industry, ultimately having a direct impact on strengthening the Company’s business fundamentals.

“Receiving the Best Pharmaceutical CDMO & Global Expansion Leader award from this industry news portal is a truly proud milestone for PYFA. Leading the CDMO business line for the Indonesia region, we are committed to being the strategic partner of choice for multinational corporations and top leading companies in Indonesia by continuously delivering innovative products backed by the most extensive CDMO services in its class. High client demand and current positive industry growth trends are directly reflected in PYFA’s overall performance, where the CDMO business line has consistently served over the past two years as the primary growth engine behind the Company’s revenue surge, which grew 43.7% to IDR 2.76 trillion, with gross margins maintaining a strong 21.1%. Moving forward, we will continue to elevate service standards and product innovation to deliver the best added value to all business partners and stakeholders,” expressed Savira Tjan, Head of CDMO PYFA.

PYFA’s strength as a strategic B2B partner is reflected in its track record of CDMO innovation and toll-in services trusted by various world-class pharmaceutical principals, as well as its initiative to develop the first New Chemical Entity (NCE) in Indonesia. In international markets, the facility of PYFA’s subsidiary, Probiotec in Kemps Creek, New South Wales, Australia, is fully operational following the consolidation of three Sydney locations and holds Therapeutic Goods Administration (TGA) certification, Halal certification, and the highest sustainable building rating, Green Star 6 Star (World Leadership), from the GBCA. Meanwhile domestically, PYFA is strengthening its manufacturing ecosystem through PT Ethica Industri Farmasi in Cikarang by completing the construction of the Sterile Injectable Production Facility (Line 3), which features three times the capacity of previous lines and is scheduled to enter commercial production in early 2027 to address tight global sterile injection capacity, alongside growth in the Over-the-Counter (OTC) segment through PYFAHEALTH and PYFAESTHETIC.

Strengthening local production capabilities and technology transfer partnerships through PYFA’s CDMO and contract manufacturing schemes also represents a strategic step toward addressing structural healthcare challenges in Indonesia. According to data from the Indonesian Food and Drug Authority (BPOM RI), Indonesia is the largest pharmaceutical market in the ASEAN region with a market value reaching approximately USD 11 billion (equivalent to IDR 146 trillion for pharmaceutical products and IDR 38 trillion for medical devices), yet it still relies heavily on imports for active pharmaceutical ingredients (APIs) at around 80% to 94%, as well as full reliance on imported raw materials for biological and biosimilar products. On the other hand, referring to the Indonesian Health Survey (SKI) report by the Health Policy Development Agency (BKPK) of the Ministry of Health of the Republic of Indonesia, demographic dynamics and public lifestyle shifts are driving high prevalence rates of Non-Communicable Diseases (NCDs) and degenerative conditions such as hypertension, diabetes mellitus, heart disease, and cancer, which require a sustainable supply of prescription medicines, sterile injectable formulations, and innovative therapies across national healthcare facilities.

About PYFA

PT Pyridam Farma Tbk, also known as PYFA, is a public pharmaceutical company listed on the Indonesia Stock Exchange (Ticker: PYFA). PYFA operates several business units producing prescription medicines in various forms, including tablets, capsules, creams, and injections. PYFA also has several well-known subsidiaries, including PT Holi Pharma, PT Ethica Industri Farmasi, and Probiotec Multipack.